WHO recommends not using Indian cough syrups linked to Uzbekistan deaths

2023-01-11
专利侵权
Jan 11 (Reuters) - The World Health Organization on Wednesday said that two cough syrups made by India's Marion Biotech should not be used for children, after the products were linked to 19 deaths in Uzbekistan.
Analysis by Uzbekistan's health ministry showed the syrups, Ambronol and DOK-1 Max, contained a toxic substance, ethylene glycol. The syrups were administered in doses higher than the standard for children, either by their parents, who mistook it for an anti-cold remedy, or on the advice of pharmacists, according to the analysis.
So far, Marion has not provided guarantees to WHO on the safety and quality of these products, the agency said. Shortly after the series of deaths were reported in Uzbekistan, India's health ministry suspended production at the company. According to a recent report, India's Uttar Pradesh state has suspended Marion's production license.
Marion did not immediately respond to a Reuters request for comment. Last week, the Uzbek state security service arrested four people in an investigation into the cough-syrup related deaths of 19 children.
The Uzbekistan case follows deaths of at least 70 children in Gambia that a parliamentary committee had linked to cough and cold syrups manufactured by New Delhi-based Maiden Pharmaceuticals. The company denied any wrongdoing and Indian government inspectors found no contamination in test samples.
Our Standards: The Thomson Reuters Trust Principles.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。